Grifols warns recovery could be threatened; puts the brakes on acquisitions and suspends dividends


Link Securities | The daily made echo on Monday of a risk report Grifols presented to the US regulator SEC. In the document, the Spanish multinational pharmaceutical company admitted the recovery could be threatened by the pressure from a competition which has increasingly more resources and already offers solutions similar to those of the listed Catalan firm.

Grifols warns in the report that its rivals are tough: “Our main competitors are Takeda, CSL Behring and Octapharma…and some of them have financial resources which are substantially greater than ours”. So the company has put the breaks on acquisitions and suspended dividend payments while it seeks 300 million euros between divestments and savings measures.

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.